Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids): evaluation report
01 Pre-Meeting Briefing prepared by NICE
02 Submission from the technology manufacturer Roche Products
03 NICE request to the manufacturer for clarification on their submission
04 Manufacturer clarification response
05 Consultee submission - British Association of Dermatologists
06 Consultee submission - British Association for Paediatric Nephrology
07 Consultee submission - British Society for Paediatric and Adolescent Rheumatology
08 Consultee submission - British Society for Rheumatology
09 Consultee submission - Royal College of Nursing
10 Consultee submission - Vasculitis UK
11 Consultee submission – UKVAS
12 Clinical expert personal perspective – Harper
13 Clinical expert personal declaration – Lanyon
14 Patient expert personal declaration – Mills
15 Patient expert personal perspective – Ranyell
16 Evidence Review Group Report prepared by School of Health and Related Research (ScHARR)
17 Evidence Review Group Report Erratum
18 Manufacturer factual accuracy check of Evidence Review Group report
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
If you have any feedback on the new format please contact the Project Manager for this appraisal.
Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids): evaluation report
23 July 2013 (7.09 Mb 14 sec) |
This page was last updated: 22 July 2013